Low-Dose Radiation Therapy for Severe COVID-19 Pneumonia

This phase II trial studies low-dose radiation therapy as a treatment for patients with severe COVID-19 pneumonia to improve clinical status.

Inclusion Criteria:Have had a positive test confirming the diagnosis of COVID-19;Have had clinical signs of severe acute respiratory syndrome or pneumonia (dyspnea, cough, with need for oxygen support at the time of enrollment);Have visible consolidations/ground glass opacities on chest x-ray or computed tomography;Have been on ventilator support for no longer than 5 calendar days prior to the schedule date of delivery of low-dose radiation therapy;They voluntarily participate in this clinical trial, gave informed consent and signed the informed consent form.Exclusion Criteria:Have received chest radiotherapy beforeBacteria, fungi and other infections other than novel coronavirus infection;Combined with severe primary diseases such as cardiovascular, cerebrovascular, liver, kidney, hematopoietic and endocrine system or immune system diseases (the upper limit of liver function ALT and AST> normal reference value, the upper limit of Scr> normal reference value, poor blood glucose control);Mental retardation, mental disorders;Planned pregnancy, pregnancy, lactation women and during the trial;Allergy constitution or allergy to the drug ingredients and excipients of this test;Participated in other clinical trials in the recent 1 month;The Investigator does not considered appropriate to participate in this clinical trial.